Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes

Review of Diabetic Studies

Volumn 9, Issue 4, 2012, Pages 338-347

  Mandrup Poulsen, Thomas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anakinra; Beta cell; Biologics; Etanercept; Immune intervention; Insulin secretion; Interleukin; NF kappaB; Rilonacept; TNF; Tumor necrosis factor; Type 1 diabetes

Indexed keywords

ADALIMUMAB; CANAKINUMAB; CASPASE; CRYOPYRIN; ETANERCEPT; GEVOKIZUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAZOLOQUINAZOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

CELL DIFFERENTIATION; CELL THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; IMMUNITY; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

EID: 84879522903     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2012.9.338     Document Type: Review

References (57)

1. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large populationbased cohort with long-standing childhood-onset type 1 diabetes. The Allegheny County Type 1 Diabetes Registry. Diabetes Care 2010. 33:2573-2579.
2. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes 2005. 54:2060-2069.
3. Shapiro AM. Islet transplantation type 1 diabetes. Rev Diabet Stud 2012. 9(4):320-329.
4. Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 1985. 40:424-429.
5. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008. 29:334-350.
6. Mandrup-Poulsen T, Pickersgill LM, Donath MY. Blockade of Interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010. 6:158-166.
7. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011. 11:98-107.
8. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opinion Endocrinol Diab Obesity 2010. 17:314-321.
9. Rabinovitch A, Suarez-Pinzon WL. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochem Biophys 2007. 48:159-163.
10. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Disc 2012. 11:633-652.
11. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012. 7:e30275.
12. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes. Diabetes Care 2009. 32(7):1244-1249.
13. Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Ped Diabetes 2011. 12(7):656-667.
14. Moran A, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized double-masked, placebo-controlled trials. Lancet 2013. In press.
15. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol 2007. 179:4307-4312.
16. Moosmayer D, Dübel S, Brocks B, Watzka H, Hampp C, Scheurich P, Little M, Pfizenmaier K. A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity. Ther Immunol 1995. 2(1):31-40.
17. Gururaja TL, Yung S, Ding R, Huang J, Zhou X, McLaughlin J, Daniel-Issakani S, Singh R, Cooper RD, Payan DG, Masuda ES, Kinoshita T. A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1. Chem Biol 2007. 14:1105-1118.
18. Bresnihan B. Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol Suppl. 2002. 65:39-43.
19. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006. 24(1):83-86.
20. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005. 64(5):765-766.
21. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012. 14(3):R141.
22. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNFalpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996. 45(7):881-885.
23. Dominguez H, Storgaard H, Rask-Madsen C, Hermann ST, Ihlemann N, Baunbjerg Nielsen D, Spohr C, Kober L, Vaag A, Torp-Pedersen C. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005. 42(6):517-525.
24. Paguot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000. 85(3):1316-1319.
25. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006. 166(8):902-908.
26. Wascher TC, Lindeman JHN, Sourij H, Kooistra T, Pacini G, Roden M. Chronic TNF-alpha neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Mol Med 2011. 17(3-4):189-193.
27. Mandrup-Poulsen T, Bendtzen K, Dinarello CA, Nerup J. Human tumor necrosis factor potentiates human interleukin 1 mediated rat pancreatic beta cell cytotoxicity. J Immunol 1987. 139(12):4077-4082.
28. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011. 117:3720-3732.
29. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009. 27:229-265.
30. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010. 11(2):136-140.
31. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010. 11(10):897-904.
32. Westwell-Roper C, Dai DL, Soukhatcheva G, Potter KJ, van Rooijen N, Ehses JA, Verchere CB. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011. 187(5):2755-2765.
33. Menu P, Mayor, Zhou R, Tardivel A, Ichijo H, Mori K, Tschopp J. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis 2012. 3:e261.
34. Lerner AG, Upton JP, Praveen PV, Ghosh R, Nakagawa Y, Igbaria A, Shen S, Nguyen V, Backes BJ, Heiman M, et al. IRE1alpha induces thioredoxininteracting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab 2012. 16(2):250-264.
35. Oslowski CM, Hara T, O'Sullivan-Murphy B, Kanekura K, Lu S, Hara M, Ishigaki S, Zhu LJ, Hayashi E, Hui ST, Greiner D, Kaufman RJ, Bortell R, Urano F. Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metab 2012. 16(2):265-273.
36. Wen H, Ting JP, O'Neill LA. A role for the NLRP3 inflammasome in metabolic diseases did Warburg miss inflammation? Nat Immunol 2012. 13:352-357.
37. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009. 27:519-550.
38. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005. 52:1960-1967.
39. http://www.prnewswire.com/news-releases/twipharmaceuticals-announces-positive-phase-iib-clinical-trial-results-of-ac-201-in-patients-with-type-2-diabetes165107926.html.
40. Akeson CA, Woods CW, Hsieh LC, Bohnke RA, Ackermann BL, Chan KY, Robinson JL, Yanofsky SD, Jacobs JW, Barrett RW, Bowlin TL. AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J Biol Chem 1996. 271(48):30517-30523.
41. Sarabu R, Cooper JP, Cook CM, Gillespie P, Perrotta AV, Olson GL. Design and synthesis of small molecule interleukin-1 receptor antagonists based on a benzene template. Drug Des Discov 1998. 15:191-198.
42. Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, Beauchamp M, Leduc M, Rihakova L, Joyal JS, Nadeau S, et al. Development of a novel noncompetitive antagonist of IL-1 receptor. J Immunol 2008 180(10):6977-6987.
43. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease re-loaded: a clinical perspective. Cell 2010. 140:784-790.
44. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1 receptor antagonist in Type 2 diabetes mellitus. N Engl J Med 2007. 356(15):1517-1526.
45. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effect of interleukin-1-receptor antagonist treatment on beta-cell function in type 2 diabetes mellitus. Diabetes Care 2009. 32(9):1663-1668.
46. Cavelti-Weder C, Babiens-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, Solinger AM, Mandrup-Poulsen T, Dinarello CA, Donath MY. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012. 35(8):1654-1662.
47. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986. 29:63-67.
48. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996. 39:1005-1029.
49. Eizirik DL, Mandrup-Poulsen T. A choice of death the signal-transduction of immune-mediated beta cell apoptosis. Diabetologia 2001. 44:2115-2133.
50. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, Mandrup-Poulsen T, Herold K. Synergistic reversal of type 1 diabetes in NOD mice with anti-adaptive and innate immune modulators. Diabetes 2012. 61:145-154.
51. van Asseldonk EJ, van Poppel PC, Ballak DB, Stienstra R, Netea MG, Tack CJ. One week of treatment with the IL-1 receptor antagonist anakinra improves insulin sensitivity in patients with type 1 diabetes mellitus: results from a clinical trial. Diabetologia 2012. 55 (Suppl 1):S233.
52. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White P. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007. 92:3705-3711.
53. Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA, Zipris D. Dysregulated toll like receptor induced interleukin-1beta and interleukin-6 responses in subjects at risk for the development of type 1. Diabetes 2012. 61:2525-2533.
54. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004. 53(1):250-264.
55. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulindependent diabetes mellitus. N Engl J Med 1989. 320:550-554.
56. Mandrup-Poulsen T. IAPP boosts islet macrophage IL-1 in type 2 diabetes. Nat Immunol 2010. 11:881-883.
57. Palmer JP, Helqvist S, Spinas GA, Mølvig J, Mandrup-Poulsen T, Andersen HU, Nerup J. Interaction of beta-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans. Diabetes 1989. 38:1211-1216. Rev Diabet Stud (2012) 9:338-347.